Thursday, June 29, 2017
 
 
Company News: Page (1) of 1 - 03/20/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
MGC Diagnostics Corporation Announces Annual Meeting of Shareholders and Fiscal 2016 Year-end Letter to Shareholders
 
(March 20, 2017)

SAINT PAUL, Minn., March 20, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced details for its upcoming Annual Meeting of Shareholders and its fiscal 2016 year-end letter to shareholders.

Annual Meeting of Shareholders
MGC Diagnostics Corporation's 2017 Annual Meeting of Shareholders will be on Wednesday, March 22, 2017, beginning at 3:30 P.M. CDT. The meeting will be held at MGC's offices located at 350 Oak Grove Parkway, Saint Paul, Minnesota 555127.

Year-end Letter to Shareholders
Please click the link to view our year-end letter to shareholders which can be found in the Business Overview 2016: http://mgcdiagnostics.com/investor-relations/annual-reports.


About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and, in the United States, France and Belgium, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2016, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contacts

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mgc-diagnostics-corporation-announces-annual-meeting-of-shareholders-and-fiscal-2016-year-end-letter-to-shareholders-300426442.html

SOURCE MGC Diagnostics Corporation

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Disease, healthcare, Technology, Surgery, Science, Medical Technology, Medical, Business, Other,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • Fitness App Market 29.45% CAGR by 2021 Says a New Research Report at ReportsnReports.com
  • Home Healthcare Market Size Expected to Reach $391.41 Bn by 2021: Zion Market Research
  • Knee Implants Market Is Expected To Reach USD 13.5 Bn By 2025, Credence Research
  • C-TAC Launches Campaign to Transform Advanced Care
  • Facial Injectables Market Is Expected To Witness Growth Swiftly, Owing To Advancements In Facial Rejuvenation Procedures & Importance Of Medical Aesthetics Till 2025: Grand View Research, Inc

    Cancer
  • Novartis receives EU approval for first-line use of ZykadiaŽ in ALK-positive advanced non-small cell lung cancer (NSCLC)
  • Pharmaleads Reports Positive Phase I SAD Data with its Dual ENKephalinase Inhibitor (DENKI) PL265 for the Treatment of Neuropathic Pain
  • Low Uptake of Cancer Preventing Human Papillomavirus Vaccine Linked to Lasting Injection Fear Formed in Preschool
  • Community Health Accreditation Partner (CHAP) Announces President and CEO Departure
  • Polymedco, Inc. Acquires U.S. Distribution Rights to the PATHFAST Product Line
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines